Matches in SemOpenAlex for { <https://semopenalex.org/work/W3097777688> ?p ?o ?g. }
- W3097777688 endingPage "535" @default.
- W3097777688 startingPage "531" @default.
- W3097777688 abstract "BackgroundTrial of Rivaroxaban in AntiPhospholipid Syndrome was a prospective randomized, open‐label, noninferiority study conducted in 14 centers in Italy. Rivaroxaban was compared with warfarin for the prevention of thromboembolic events, major bleeding, and vascular death in high‐risk, triple‐positive patients with antiphospholipid syndrome.ObjectiveThe aim of this paper is to report the events during the 2‐year follow‐up after the study closure.MethodsOn January 28, 2018, the trial was prematurely stopped by adjudication and safety committee for an excess of events in the rivaroxaban group. Randomized patients were advised on trial results and those randomized to rivaroxaban were solicited to switch to warfarin. All 14 participating centers were asked and accepted to follow their patients for clinical events. This report describes the rate of events that occurred between January 28, 2018, and January 28, 2020.ResultsOf 120 randomized patients, 115 were available for follow‐up. Outcome events were two in six (33.3%) patients who remained on direct oral anticoagulants (DOACs) and six in 109 (5.7%) patients on warfarin (hazard ratio [HR] 6.9; 95% confidence interval [CI] 1.4‐34.5, P = .018). The two patients on DOACs (one taking dabigatran and one taking rivaroxaban) suffered from thromboembolic events, whereas of the six patients with composite outcomes on warfarin, three had thromboembolic events (HR for thrombosis 13.3; 95% CI 2.2‐79.9, P = .005).ConclusionThese data further support the use of warfarin in high‐risk patients with antiphospholipid syndrome." @default.
- W3097777688 created "2020-11-09" @default.
- W3097777688 creator A5003292078 @default.
- W3097777688 creator A5022945946 @default.
- W3097777688 creator A5032826393 @default.
- W3097777688 creator A5035630918 @default.
- W3097777688 creator A5039653787 @default.
- W3097777688 creator A5039927165 @default.
- W3097777688 creator A5047717272 @default.
- W3097777688 creator A5054015102 @default.
- W3097777688 creator A5058256497 @default.
- W3097777688 creator A5058320262 @default.
- W3097777688 creator A5060145771 @default.
- W3097777688 creator A5061119590 @default.
- W3097777688 creator A5067095323 @default.
- W3097777688 creator A5068009941 @default.
- W3097777688 creator A5075020183 @default.
- W3097777688 creator A5075069140 @default.
- W3097777688 creator A5079447134 @default.
- W3097777688 creator A5087432225 @default.
- W3097777688 date "2021-02-01" @default.
- W3097777688 modified "2023-10-11" @default.
- W3097777688 title "Trial of Rivaroxaban in AntiPhospholipid Syndrome (TRAPS): Two‐year outcomes after the study closure" @default.
- W3097777688 cites W2016875529 @default.
- W3097777688 cites W2109613206 @default.
- W3097777688 cites W2119266650 @default.
- W3097777688 cites W2142444723 @default.
- W3097777688 cites W2158593099 @default.
- W3097777688 cites W2339926357 @default.
- W3097777688 cites W2344014234 @default.
- W3097777688 cites W2587884398 @default.
- W3097777688 cites W2791629902 @default.
- W3097777688 cites W2813643485 @default.
- W3097777688 cites W2854123595 @default.
- W3097777688 cites W2886953225 @default.
- W3097777688 cites W2907794812 @default.
- W3097777688 cites W2946160313 @default.
- W3097777688 cites W2949224491 @default.
- W3097777688 cites W2967456605 @default.
- W3097777688 cites W2980869818 @default.
- W3097777688 cites W2981578628 @default.
- W3097777688 cites W2982117607 @default.
- W3097777688 cites W2989714602 @default.
- W3097777688 cites W2991212949 @default.
- W3097777688 cites W3006613364 @default.
- W3097777688 cites W3016802336 @default.
- W3097777688 cites W3026382098 @default.
- W3097777688 cites W3027952476 @default.
- W3097777688 doi "https://doi.org/10.1111/jth.15158" @default.
- W3097777688 hasPubMedId "https://pubmed.ncbi.nlm.nih.gov/33128325" @default.
- W3097777688 hasPublicationYear "2021" @default.
- W3097777688 type Work @default.
- W3097777688 sameAs 3097777688 @default.
- W3097777688 citedByCount "33" @default.
- W3097777688 countsByYear W30977776882021 @default.
- W3097777688 countsByYear W30977776882022 @default.
- W3097777688 countsByYear W30977776882023 @default.
- W3097777688 crossrefType "journal-article" @default.
- W3097777688 hasAuthorship W3097777688A5003292078 @default.
- W3097777688 hasAuthorship W3097777688A5022945946 @default.
- W3097777688 hasAuthorship W3097777688A5032826393 @default.
- W3097777688 hasAuthorship W3097777688A5035630918 @default.
- W3097777688 hasAuthorship W3097777688A5039653787 @default.
- W3097777688 hasAuthorship W3097777688A5039927165 @default.
- W3097777688 hasAuthorship W3097777688A5047717272 @default.
- W3097777688 hasAuthorship W3097777688A5054015102 @default.
- W3097777688 hasAuthorship W3097777688A5058256497 @default.
- W3097777688 hasAuthorship W3097777688A5058320262 @default.
- W3097777688 hasAuthorship W3097777688A5060145771 @default.
- W3097777688 hasAuthorship W3097777688A5061119590 @default.
- W3097777688 hasAuthorship W3097777688A5067095323 @default.
- W3097777688 hasAuthorship W3097777688A5068009941 @default.
- W3097777688 hasAuthorship W3097777688A5075020183 @default.
- W3097777688 hasAuthorship W3097777688A5075069140 @default.
- W3097777688 hasAuthorship W3097777688A5079447134 @default.
- W3097777688 hasAuthorship W3097777688A5087432225 @default.
- W3097777688 hasConcept C126322002 @default.
- W3097777688 hasConcept C141071460 @default.
- W3097777688 hasConcept C168563851 @default.
- W3097777688 hasConcept C207103383 @default.
- W3097777688 hasConcept C2776301958 @default.
- W3097777688 hasConcept C2776874634 @default.
- W3097777688 hasConcept C2778661090 @default.
- W3097777688 hasConcept C2778810321 @default.
- W3097777688 hasConcept C2779161974 @default.
- W3097777688 hasConcept C2780868729 @default.
- W3097777688 hasConcept C44249647 @default.
- W3097777688 hasConcept C71924100 @default.
- W3097777688 hasConceptScore W3097777688C126322002 @default.
- W3097777688 hasConceptScore W3097777688C141071460 @default.
- W3097777688 hasConceptScore W3097777688C168563851 @default.
- W3097777688 hasConceptScore W3097777688C207103383 @default.
- W3097777688 hasConceptScore W3097777688C2776301958 @default.
- W3097777688 hasConceptScore W3097777688C2776874634 @default.
- W3097777688 hasConceptScore W3097777688C2778661090 @default.
- W3097777688 hasConceptScore W3097777688C2778810321 @default.
- W3097777688 hasConceptScore W3097777688C2779161974 @default.
- W3097777688 hasConceptScore W3097777688C2780868729 @default.